ERNA-101 Phase 1 Study Planned for Q4 2026: Complete Tumor Clearance in Preclinical Ovarian Cancer Models
Market Chameleon (Wed, 15-Jul 9:52 AM)
ERNA-101 Combination Therapy Achieves 67% Complete Tumor Clearance in Independent Ovarian Cancer Study
Market Chameleon (Wed, 15-Jul 8:10 AM)
Ernexa’s ERNA-101 Moves Closer to Clinical Trials: GMP Manufacturing Complete, IND Submission Expected in Q3 2026
Market Chameleon (Wed, 17-Jun 9:18 AM)
ERNA-101 Shows Promising Results in Ovarian Cancer—Clinical Data Reveals 100% Survival in Preclinical Studies
Market Chameleon (Tue, 12-May 11:14 AM)
ERNA-101 Shows Complete Tumor Elimination and 100% Survival in Ovarian Cancer Models—What Sets Ernexa Therapeutics Apart?
Market Chameleon (Mon, 11-May 9:21 AM)
